Skin Disorders Therapeutics
1. Leqselvi patent expiration
Treatment: Treatment of adult patients with alopecia areata
LEQSELVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12247034 | SUN PHARMA | Crystalline form of deuruxolitinib phosphate |
May, 2044
(18 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12285432 | SUN PHARMA | Treatment of hair loss disorders with deuterated JAK inhibitors |
Aug, 2042
(16 years from now) | |
| US11919907 | SUN PHARMA | Deuterated JAK inhibitor and uses thereof |
May, 2041
(15 years from now) | |
| US10561659 | SUN PHARMA | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US12076323 | SUN PHARMA | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US12364699 | SUN PHARMA | Method Of Treating Hair Loss Disorders |
Oct, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
2. Litfulo patent expiration
Treatment: Method of treating severe alopecia areata in adults and adolescents 12 years and older by administering ritlectinib
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12116368 | PFIZER | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Oct, 2041
(15 years from now) | |
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12077533 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Dosage: CAPSULE
More Information on Dosage
LITFULO family patents
3. Picato patent
expiration
Treatment: Treatment of actinic keratosis; Use of ingenol mebutate to treat actinic keratosis; To stimulate the immune system to induce t cell proliferation; To inhibit the proliferative activity of neoplastic c...
PICATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6787161 | LEO | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8536163 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US6432452 | LEO | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US6844013 | LEO | Methods of stimulating the immune system |
Dec, 2018
(7 years ago) | |
| US7410656 | LEO | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8716271 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US9861603 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US8735375 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US9820959 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US9789078 | LEO | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(7 years from now) | |
| US9833429 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US8372827 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US8377919 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US8372828 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US9833428 | LEO | Therapeutic compositions |
Dec, 2026
(9 months from now) | |
| US8278292 | LEO | Therapeutic compositions |
Jul, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
| M(M-169) | Nov 19, 2018 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Dosage: GEL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
4. Wayrilz patent expiration
Treatment: Method for treating adult patients with persistent or chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment, by achieving a platelet count of at least 50,...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994576 | GENZYME | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US9266895 | GENZYME | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US8940744 | GENZYME | Pyrazolopyrimidine Compounds As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US11708370 | GENZYME | Solid Forms Of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile |
Feb, 2041
(15 years from now) | |
| US9580427 | GENZYME | Kinase Inhibitors |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178818 | GENZYME | Methods For Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile |
Oct, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2030 |
Drugs and Companies using RILZABRUTINIB ingredient
NCE-1 date: 29 August, 2029
Market Authorisation Date: 29 August, 2025
Dosage: TABLET
More Information on Dosage
WAYRILZ family patents